Another study stemming from the COMPASS trial discovered that the measurement of GATA6 expression in tumors using RNA in situ hybridization serves as a robust surrogate biomarker for distinguishment between classical and basal-like subtypes of PDA.61 This evidence concerns the gene GATA6 and Patent ductus arteriosus.